Vascular Ehlers-Danlos Syndrome (VEDS)Symptoms, Doctors, Treatments, Advances & More
Learn About Vascular Ehlers-Danlos Syndrome (VEDS)
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Heart And Vascular Center At Durham Outpatient Center
Angela Yetman is a Cardiologist and a Pediatric Cardiologist practicing medicine in Omaha, Nebraska. She has been practicing medicine for over 35 years. Dr. Yetman is rated as an Advanced provider by MediFind in the treatment of Vascular Ehlers-Danlos Syndrome (VEDS). She is also highly rated in 7 other conditions, according to our data. Her clinical expertise encompasses Turner Syndrome, Marfan Syndrome, Congenital Contractural Arachnodactyly, and Congenital Heart Disease (CHD).
Salma Adham practices practicing medicine in Montpellier, France. Ms. Adham is rated as an Elite expert by MediFind in the treatment of Vascular Ehlers-Danlos Syndrome (VEDS). She is also highly rated in 2 other conditions, according to our data. Her clinical expertise encompasses Vascular Ehlers-Danlos Syndrome (VEDS), Ehlers-Danlos Syndrome (EDS), Pseudoxanthoma Elasticum, and Meige Disease.
The Association Of University Physicians
Peter Byers is a Medical Genetics provider practicing medicine in Seattle, Washington. Dr. Byers is rated as an Elite provider by MediFind in the treatment of Vascular Ehlers-Danlos Syndrome (VEDS). He is also highly rated in 3 other conditions, according to our data. His clinical expertise encompasses Ehlers-Danlos Syndrome (EDS), Vascular Ehlers-Danlos Syndrome (VEDS), Osteogenesis Imperfecta, and Hypotonia. Dr. Byers is currently accepting new patients.
Summary: This research study will investigate whether people with vascular Ehlers-Danlos syndrome (vEDS), a rare inherited condition, have problems with the way their body stores and uses fat (adipose tissue). vEDS is caused by changes in a gene called COL3A1, which makes a protein important for the structure of many tissues. While vEDS is best known for making blood vessels fragile, there is some early ev...
Summary: This is a prospective, Phase 3, randomized, double-blind, placebo-controlled efficacy study to evaluate celiprolol in patients genetically confirmed as COL3A1-positive vEDS using a decentralized clinical trial design.